IN-OFFICE CARDIOLOGY IMAGING SERVICES
NUCLEAR MEDICINE IMAGING SYSTEMS
digirad_corp
       
 
 
 

COMPANY>

INVESTOR>

MANAGEMENT>

BOARD>

PRESS>

CAREER>
 
s
  s

DIGIRAD CORPORATION REPORTS 2010 FINANCIAL RESULTS
Digirad Corporation (NASDAQ: DRAD) today reported fourth quarter revenue of $14.7 million, 2010 full-year revenue of $56.2 million and an ending cash and available-for-sale securities balance of $30.2 million at December 31, 2010.

 

CMS ANNOUNCES REIMBURSEMENT INCREASE
The Centers for Medicare & Medicaid Services announced an improved 16% reimbursement increase on SPECT nuclear imaging devices today. In January of this year, reimbursements had been cut by 36%, however, with the 16% increase the total reimbursement cut will amount to 20%. All reimbursements will be adjusted to reflect the new rate of 20% effective immediately and all payments made after January 1st will be reimbursed the 16% difference.
s   s
DIGIRAD RECEIVES CE MARK FOR ERGO(TM) SOLID-STATE, GENERAL IMAGING NUCLEAR MEDICINE CAMERA
Digirad Corporation (NASDAQ: DRAD) today announced that it has received Conformite Europeene (CE) Mark approval enabling the Company to market and distribute its ergo™ large field-of-view, general-purpose portable imaging system throughout Europe and other countries governed by the CE body.
 
Digirad is proud to be present at most relevant tradeshows in the US and also internationally.
tradeshows
 
 
spacer
 
 
   
 
     
cardiology imaging services & systems from Digirad - ph 800 947 6134 - copyright © Digirad Corp. - design by audacity